Atezolizumab + Talazoparib for Small Cell Lung Cancer
What You Need to Know Before You Apply
What is the purpose of this trial?
This phase II trial studies whether atezolizumab in combination with talazoparib works better than atezolizumab alone as maintenance therapy for patients with SLFN11-positive extensive-stage small cell lung cancer. Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. PARPs are proteins that help repair damage to DNA, the genetic material that serves as the body's instruction book. Changes (mutations) in DNA can cause tumor cells to grow quickly and out of control, but PARP inhibitors like talazoparib may keep PARP from working, so tumor cells can't repair themselves, and they stop growing. Giving atezolizumab in combination with talazoparib may help lower the chance of extensive-stage small cell lung cancer growing and spreading compared to atezolizumab alone.
Will I have to stop taking my current medications?
The trial requires that participants do not take certain medications, such as strong P-glycoprotein inhibitors, P-glycoprotein inducers, or breast cancer resistance protein inhibitors, within 7 days before starting the trial and during the trial. If you are taking these medications, you may need to stop them.
Is the combination of Atezolizumab and Talazoparib safe for humans?
How is the drug combination of Atezolizumab and Talazoparib unique for treating small cell lung cancer?
The combination of Atezolizumab and Talazoparib is unique because Atezolizumab is a PD-L1 inhibitor that helps the immune system attack cancer cells, while Talazoparib is a PARP inhibitor that prevents cancer cells from repairing their DNA, making this a novel approach for treating small cell lung cancer.12467
What data supports the effectiveness of the drug combination Atezolizumab and Talazoparib for Small Cell Lung Cancer?
Atezolizumab, when combined with chemotherapy, has been shown to improve survival in patients with extensive-stage small cell lung cancer. Talazoparib is effective in treating certain types of breast cancer, and it is being explored for use in other cancers, suggesting potential benefits when combined with Atezolizumab.12578
Who Is on the Research Team?
Nagla Abdel Karim
Principal Investigator
SWOG Cancer Research Network
Are You a Good Fit for This Trial?
This trial is for adults with extensive-stage small cell lung cancer (ES-SCLC) confirmed by biopsy, who have completed initial treatment without disease progression or severe immune-related side effects. They must not have mixed SCLC/NSCLC histology, active pneumonitis, uncontrolled diseases like diabetes or infections, and no prior immunotherapy for SCLC. Participants need adequate organ function and cannot be pregnant or breastfeeding.Inclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive atezolizumab alone or in combination with talazoparib as maintenance therapy
Follow-up
Participants are monitored for safety and effectiveness after treatment
Long-term follow-up
Participants are monitored for overall survival
What Are the Treatments Tested in This Trial?
Interventions
- Atezolizumab
- Talazoparib
Talazoparib is already approved in United States, European Union for the following indications:
Find a Clinic Near You
Who Is Running the Clinical Trial?
National Cancer Institute (NCI)
Lead Sponsor